Institutional Owners May Consider Drastic Measures as Altimmune, Inc.'s (NASDAQ:ALT) Recent US$56m Drop Adds to Long-term Losses

Simply Wall StJan 2 05:56 ET

Jim Cramer on Altimmune, Inc. (ALT): 'Healthcare Is So Out Of Fashion'

Yahoo FinanceDec 28, 2024 15:39 ET

Most Shorted Stocks on Wall Street Heading Into 2025: BYND, KSS, GRPN, and More

Seeking AlphaDec 27, 2024 11:04 ET

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Yahoo FinanceDec 25, 2024 06:26 ET

Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination

Yahoo FinanceDec 24, 2024 14:40 ET

B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsDec 20, 2024 14:31 ET · Ratings